Typically used as a therapy for Type 2 diabetics, The European commission approves SGLT2 inhibitors for Type 1 diabetics who are on insulin and have a BMI of at least 27kg/m2. It is geared towards type 1 diabetics who despite optimal insulin therapy can not garner adequate glycemic control.
Read more here on my Facebook page This Diabetic Sees Things Differently